Sequana Medical said it has received investigational device exemption approval from the FDA to conduct a pivotal study of its Alfapump device for patients with recurrent or refractory ascites due to liver cirrhosis. Alfapump is a fully implantable pump designed to continuously remove excess abdominal fluid in patients with liver disease. Zurich-based Sequana has applied to […]
Xtant Medical CEO Goldberger steps down | Personnel Moves | February 3, 2017
Xtant Medical (NYSE:XTNT) said that CEO Dan Goldberger resigned effective Jan. 21 “to pursue other interests.” The Belgrade, Mont.-based company, which was formed after Bacterin paid $86 million for spinal implant maker X-Spine Systems, said president Carl O’Connell will step in as interim CEO while the company’s board “contemplates the permanent CEO,” according to a […]
Burberry poaches Smith & Nephew CFO Brown | Personnel Moves for July 12, 2016
Burberry poaches Smith & Nephew CFO Brown Smith & Nephew (NYSE:SNN) said yesterday that CFO Julie Brown is leaving the company in January 2017 after 4 years on the job at the British healthcare products giant. Brown, who was named finance chief in November 2012 and assumed the role in February 2013, is moving to […]
Sequana Medical adds $9m for Alfapump implantable pump
Sequana Medical said today that it added $9.3 million to the $26 million Series C round it raised last year, as it readies for a U.S. clinical trial of its Alfapump implantable pump. Zurich-based Sequana said existing backers NeoMed Management, VI Partners, Biomed Invest, Capricorn Health-tech Fund, Entrepreneurs Fund and Life Science Partners put up $5.5 million. New investors […]
SI-Bone announces big plans for its newly raised $33 million | Medtech funding stories for the week of Apr. 28, 2014
Funding: Sequana raises $26.2M for implantable bladder pump
Switzerland-based medtech company Sequana Medical has big plans for its newly-closed $26.2 million (CHF 23 million) Series C financing round, hoping to use the funds to widen its global sales and begin penetrating the U.S. market.
St. Jude’s Ilumien hybrid wins CE Mark | Regulatory Roundup
St. Jude Medical Inc. (NYSE:STJ) landed CE Mark approval in the European Union for what it bills as the first and only hybrid diagnostic imaging system to combine optical coherence tomography and fractional flow reserve technology into a single platform.
Health care: Obama’s insurance mandate gets mixed reception in court
MASSDEVICE ON CALL — A panel of federal appellate judges heard arguments yesterday regarding President Barack Obama’s health care overhaul to determine whether the administration can constitutionally require citizens to buy health insurance.
During 90 minutes of oral arguments, the three-member panel of judges gave both the administration and its challengers a mixed reception.
Two judges on the three-member panel were appointed by Republican presidents.
